Abstract
CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3), was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with localized breast cancer had CA 15:3 levels greater than 25 U ml-1, and levels increased with tumour size. CA 15:3 levels greater than 25 U ml-1 were found in 54% of patients with nodal involvement and in 91% of patients with metastatic breast disease. Measurement of CA 15:3 in 70 women with metastatic breast cancer and a normal CEA revealed positive CA 15:3 levels at diagnosis of the first metastasis in 66% of cases; 63% of these patients could be monitored with CA 15:3.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Pons-Anicet, D., Krebs, B., Mira, R. et al. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer 55, 567–569 (1987). https://doi.org/10.1038/bjc.1987.115
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.115
This article is cited by
-
The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer
BMC Cancer (2022)
-
Application of carbon nanotubes layered on silicon wafer for the detection of breast cancer marker carbohydrate antigen 15-3 by immuno-polymerase chain reaction
Journal of Materials Science: Materials in Medicine (2014)
-
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Breast Cancer Research and Treatment (2009)
-
Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis
Annals of Nuclear Medicine (2000)
-
Tumor marker levels elevate false-positively in postsurgical Breast Cancer patients with high sgpt levels or with receiving oral 5-FU or its derivatives
Breast Cancer (1999)
